Particle-Enhanced Turbidimetric Immunoassays Market

Particle-Enhanced Turbidimetric Immunoassay Market Forecast and CAGR

According to the latest research by Fact.MR, Particle-Enhanced Turbidimetric Immunoassay market is set to experience significant growth during the year 2021-2031. With various researches finding applications in management of various diseases, this market will see a steady growth over the forecast period of 2021-2031. Availability and readiness to fund innovations in the current market will mark as a turning point in its growth.

What is driving the demand for Particle-Enhanced Turbidimetric Immunoassay Market?

Biggest driver for this market is that this technique is very swift and can give the desired reading within 10 minutes from its initiation. This will increase the number of samples analysed daily.

In a comparative study conducted at Buehlmann labs, PETIA gave superior quality of results with it higher performance than chemiluminescent immunoassay. Making the quality of PETIA acquired data a major player in driving the demand for this market

Particle-Enhanced Turbidimetric Immunoassays or PETIA is a biochemical process which uses optical change i.e. change in opaqueness caused by the agglutination of immunoparticles in the sample. These immunopartilcles are nothing but nanoparticles coated with antibodies. Their reaction with taken sample makes the mixture cloudy. A monochromatic light is then passed through the mixture to determine the opaqueness of turbidity of the mixture. Based on the absorption of light and pre-determined calibrations as per known and standardized concentrations, quantitative measurements of body fluid components like proteins, pathogens, serums, urine, plasma, etc can then be taken.

Another crucial driver which can drive the demand for PETIA is its flexibility, as it can be integrated with any kind of chemical analysers and can be easily made a part of existing laboratory infrastructures.

PETIA & Calprotectin

Researcher at Uppsala University in Norway has developed a prototype of PETIA which has the capability of measuring the calprotectin levels in the serum or the plasma. This technology can be used in getting the calprotectin levels in inflammatory bowel disorders as this serum is called the inflammation marker for the human body. Innovative approaches like this to the already existing technologies is what will drive the market in a profitable direction.

U.S and Canada Particle-Enhanced Turbidimetric Immunoassay Market

State of the art research facilities and technological advancements have made US the most lucrative market in this field. The presence of key players in the market will play an important role in bringing novel innovation in this market. Furthermore, the increasing prevalence of infectious diseases offer lucrative opportunities for the players, enabling the launch of novel immunoassay products, for timely identification of various diseases. This in turn expected to drive the particle-enhanced turbidimetric immunoassay demand in the region.

Europe Particle-Enhanced Turbidimetric Immunoassay Market

Europe has a rising prevalence of infectious diseases, also the geriatric population here is on a rise. According to 2019 data by Eurostat, over 90.4 million Europeans fall under geriatric population. The innovative and novel approaches to traversing diverse applications of a single process is what makes Europe a second most lucrative market. This will positively boost the market during the forecast period.

Key Players for Eureopean region are Gentian Diagnostics ASA, Buehllman Lbs, Roche.

Who are the key manufacturing supplying companies in Particle-Enhanced Turbidimetric Immunoassay Market?

Key manufacturers and suppliers in the market are:

• Gentian Diagnostics ASA
• Eurospital
• Calpro
• Thermo-Fisher Scientific
• Buehlmann
• Biotec
• Abbott Laboratories
• F.Hoffmann-La Roche
• Siemens AG
• Danaher Corporation
• Diasorin SPA
• Sysmex Corporation
• Biomerieux SA
• QIAGEN
• Agilent Technologies, Inc

Particle-Enhanced Turbidimetric Immunoassays Market Report Highlights:

• Detailed overview of parent market
• Changing market dynamics in the industry
• In-depth market segmentation
• Historical, current and projected market size in terms of volume and value
• Recent industry trends and developments
• Competitive landscape
• Strategies of key players and products offered
• Potential and niche segments, geographical regions exhibiting promising growth
• A neutral perspective on market performance
• Must-have information for market players to sustain and enhance their market footprint

Key Segments –

• By Application:

  • Infectious Diseases
  • Endocrinology
  • Cardiology
  • Oncology
  • Bone and Mineral Diseases
  • Autoimmune Disorders
  • Others

• By End User:

  • Hospitals
  • Academic and Research Institutions
  • Pharmaceutical and Biotechnology Companies
  • Others

• By Region:

  • North America
  • Latin America
  • Europe
  • South Asia
  • East Asia
  • Oceania
  • Middle East & Africa

The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.

NOTE: Although care has been taken to maintain the highest levels of accuracy in reports, recent market/vendor-specific changes may take time to reflect in the analysis.